Calcimedica, INC 8-K filings

CalciMedica reported Q2 2026 results, announcing a $49 million private placement to advance its pulmonary hypertension program and providing updates on its Auxora and CM5480 candidates.

CalciMedica, Inc. announced an expansion of its Board of Directors with the appointment of Dr. Evgeny Zaytsev and the upcoming retirement of director Fred Middleton.

CalciMedica has entered into a definitive securities purchase agreement for a private placement of up to approximately $49 million to advance its pulmonary hypertension program.

CalciMedica has amended its loan agreement with Avenue Capital, extending the maturity date to 2029 and lowering warrant exercise prices to $1.00.

CalciMedica announced its first quarter 2026 financial results, highlighting progress in its Auxora program for acute pancreatitis and advancement of its CM5480 candidate for pulmonary hypertension, alongside a net income of $5.0 million.

CalciMedica, Inc. received notices from Nasdaq regarding non-compliance with minimum market value and bid price requirements, risking delisting.

CalciMedica announced its 2025 financial results, discontinued the AKI KOURAGE trial due to a mortality imbalance but no drug toxicity, and advanced Auxora for acute pancreatitis while progressing CM5480 for PAH.

CalciMedica, Inc. announced the discontinuation of its Phase 2 KOURAGE clinical trial, leading to an extension of its cash runway into the fourth quarter of 2026.

CalciMedica discontinues its Phase 2 KOURAGE clinical trial for Auxora in acute kidney injury due to an Independent Data Monitoring Committee safety recommendation.

CalciMedica announced its third quarter 2025 financial results, highlighting ongoing enrollment in its Phase 2 KOURAGE trial and positive FDA discussions for a pivotal AP trial.

CalciMedica, Inc. announced an increase in its at-the-market equity offering program to a maximum aggregate offering price of $9.7 million.

CalciMedica reports ongoing clinical trial enrollment and productive FDA discussions for Auxora, alongside an increased net loss for Q2 2025.

CalciMedica, Inc. announced that its stockholders approved an amendment to the 2023 Equity Incentive Plan to increase authorized shares by 600,000, along with the re-election of three Class I directors and the ratification of its independent auditor.

CalciMedica, Inc. announced the appointment of Baker Tilly US, LLP as its new independent registered public accounting firm, effective June 3, 2025, following the merger of its previous auditor, Moss Adams LLP, with Baker Tilly.

CalciMedica announced its Q1 2025 financial results, highlighting clinical trial progress and corporate developments, with cash runway extending into mid-2026.

CalciMedica announced its 2024 financial results, highlighting clinical trial progress and corporate developments, including ongoing enrollment in the Phase 2 KOURAGE trial and a strengthened leadership team.

CalciMedica has secured a credit facility for up to $32.5 million to support the development of its product pipeline and extend its cash runway.

CalciMedica's post-hoc analysis of the CARDEA trial shows Auxora significantly reduced mortality in COVID-19 pneumonia patients with acute kidney injury (AKI).

CalciMedica reports the resignation of Eric Bjerkholt from the board and the appointment of Alan Glicklich, M.D., as a new Class I director.

CalciMedica has filed a prospectus supplement to resume its at-the-market offering, aiming to raise up to $4.45 million through the sale of common stock.

CalciMedica reported positive results from its Phase 2b CARPO trial for Auxora in acute pancreatitis, along with financial updates and progress in other clinical trials.

CalciMedica has appointed Stephen Bardin as its new Chief Financial Officer, effective after the filing of the company's Q3 2024 report, replacing interim CFO Dan Geffken.

CalciMedica has announced the pricing of a public offering of 2,720,000 shares of its common stock at $3.75 per share, expected to generate gross proceeds of $10.2 million.

CalciMedica has announced a proposed underwritten public offering of its common stock and provided a preliminary cash balance update as of September 30, 2024.

CalciMedica's Auxora demonstrates significant efficacy in treating acute pancreatitis with systemic inflammatory response syndrome, showing substantial reductions in respiratory failure and hospital stays.

CalciMedica's stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing the authorized shares by 1,500,000, and elected two Class I directors at the 2024 Annual Meeting.

CalciMedica reported positive topline data from its Phase 2b CARPO trial for acute pancreatitis and is advancing its pipeline with a new trial in acute kidney injury.

CalciMedica's Phase 2b CARPO trial of Auxora in acute pancreatitis met its primary objective, demonstrating a statistically significant dose response in reducing time to solid food tolerance and severe organ failure.

CalciMedica reported its first quarter 2024 financial results, highlighted by the completion of enrollment in a Phase 2b trial and progress in other clinical programs.

CalciMedica has dismissed Ernst & Young as its independent auditor and engaged Moss Adams for the fiscal year ending December 31, 2024.